NCT00020267 2024-03-04Vaccine Therapy in Treating Patients With Metastatic CancerNational Cancer Institute (NCI)Phase 1 Completed
NCT03207347 2023-09-15A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)University of FloridaPhase 2 Completed37 enrolled 15 charts
NCT02315066 2022-04-21Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566PfizerPhase 1 Completed174 enrolled 68 charts
NCT03652077 2021-11-15A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesIncyte CorporationPhase 1 Completed40 enrolled
NCT01773655 2020-07-01Clinical and Histopathologic Characteristics of BAP1 MutationsMemorial Sloan Kettering Cancer CenterCompleted196 enrolled
NCT00096083 2013-10-23Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver CancerDelcath Systems Inc.Phase 2 Completed56 enrolled
NCT00020579 2012-03-15MS-275 in Treating Patients With Advanced Solid Tumors or LymphomaNational Institutes of Health Clinical Center (CC)Phase 1 Completed75 enrolled